Company Overview

Avicanna Inc. is a Canadian biopharmaceutical company focused on the development, manufacture, and commercialization of cannabinoid‑based pharmaceutical and medical cannabis products. The company operates at the intersection of biopharmaceutical development, medical cannabis, and health data–driven research, with an emphasis on evidence‑based formulations and regulated medical markets. Its primary revenue drivers include proprietary medical cannabis products, intellectual property–backed pharmaceutical formulations, and research and development services.

Founded in 2016, Avicanna has evolved from a cannabis research startup into a vertically integrated life sciences company with clinical, pharmaceutical, and commercial capabilities. The company positions itself as a science‑first organization, emphasizing clinical validation, physician education, and pharmaceutical‑grade manufacturing standards as key strategic advantages within the global cannabinoid therapeutics market.

Business Operations

Avicanna operates through several core business lines encompassing pharmaceutical development, medical cannabis commercialization, and contract research and analytics services. The company generates revenue primarily from branded medical cannabis products sold in regulated markets, as well as from research services and intellectual property licensing. Its flagship medical cannabis brand in Canada is RHO Phyto™, which includes formulated cannabinoid products distributed through authorized medical channels.

The company controls proprietary formulations, clinical data, and manufacturing relationships supporting pharmaceutical‑grade cannabinoid products. Avicanna maintains domestic operations in Canada and international operations in Latin America, supported by wholly owned subsidiaries including Santa Marta Golden Hemp S.A.S., which provides access to cultivation, extraction, and research infrastructure. The company has also entered into distribution and commercialization partnerships with established healthcare and pharmacy networks to expand patient access.

Strategic Position & Investments

Avicanna’s strategic direction centers on expanding its portfolio of clinically supported cannabinoid pharmaceuticals and strengthening recurring revenue from regulated medical markets. Growth initiatives include advancing late‑stage pharmaceutical candidates, expanding physician‑led education programs, and increasing penetration of its proprietary medical cannabis formulations in Canada and select international markets.

The company has made targeted investments in subsidiaries and intellectual property that support long‑term pharmaceutical development, including assets related to data analytics, clinical research, and formulation science. Avicanna is actively involved in emerging therapeutic areas such as non‑opioid pain management, dermatology, and rare neurological conditions, leveraging cannabinoids as active pharmaceutical ingredients. Where timelines or commercial outcomes are uncertain, data inconclusive based on available public sources.

Geographic Footprint

Avicanna is headquartered in Canada, with its principal executive offices located in Ontario. The company maintains a strong operational presence in Latin America, particularly in Colombia, where it conducts cultivation, research, and development activities through its subsidiaries. These operations support both domestic and international supply chains for pharmaceutical and medical cannabis products.

Beyond the Americas, Avicanna’s commercial and strategic reach extends into Europe and other international medical cannabis markets through partnerships, product registrations, and research collaborations. The company’s geographic strategy emphasizes jurisdictions with established regulatory frameworks for medical cannabis and pharmaceutical cannabinoid products.

Leadership & Governance

Avicanna is led by a management team with backgrounds in pharmaceuticals, healthcare, and regulated cannabis markets, emphasizing scientific rigor and regulatory compliance. The leadership’s strategic vision prioritizes long‑term value creation through clinical validation, disciplined capital allocation, and integration with mainstream healthcare systems.

• Aras Azadian – Chief Executive Officer
• Dr. Ofir Eyal – Chief Medical Officer

The company’s governance framework aligns with Canadian public company standards, with oversight provided by an independent board of directors. Where additional executive role details are not consistently disclosed across public filings, data inconclusive based on available public sources.